Skip to content

Mapping Cancer’s Life Story

The Rest Is Science

Hosted by Hannah Fry and Michael Stevens

33m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode of The Rest Is Science, produced with Cancer Research UK, features hosts Michael Stevens and Hannah Fry interviewing Cancer Research UK chief clinician and lung cancer specialist Professor Maryam Jamal-Hanjani. The discussion covers the journey from theoretical physics to oncology, the complex mechanisms of cancer wasting syndrome known as cachexia, advanced insights gained from patient autopsy studies, and innovative preventive vaccines like LungVax. The guest and hosts explain how precision medicine, immunotherapy, and a multi-system approach to biology are shifting the future of cancer treatment and survival.

  • Cachexia disrupts normal metabolism, causing the body to dismantle muscle and fat at an accelerating rate that cannot be reversed simply by eating more. 11:19
  • Autopsy studies allow researchers to map how advanced cancers spread and evolve across difficult-to-reach organs like the brain and bones. 20:03
  • The LungVax trial is testing a vaccine for post-surgery patients to prevent early-stage lung cancer from returning or developing in healthy high-risk participants. 23:30
  • Extra-chromosomal DNA fragments float outside normal chromosomes, hold oncogenes, and are frequently found in highly aggressive cancers. 25:54

Chapters

  1. 0:00
    Hope and Community Message

    Hosts set the tone, urging listeners to leave with hope and a call to think big and build community.

  2. 0:38
    Microbubbles and Drug Delivery Innovations

    Discussion of microbubble technology and other novel delivery methods that breach the blood‑brain barrier.

  3. 1:13
    Cachexia: A Mysterious Cancer‑Related Syndrome

    Hosts explain cachexia, its prevalence, and why it remains a major unmet challenge in oncology.

  4. 3:01
    Team CanCan’s Research into Cachexia

    Introduction of Team CanCan and their efforts to understand and treat cachexia through a global research challenge.

  5. 15:14
    Mechanisms of Cachexia and Early Detection

    Exploration of the biological pathways driving cachexia and the potential for early biomarkers and interventions.

  6. 23:45
    LungVax: First Lung‑Cancer Prevention Vaccine

    Presentation of the LungVax clinical trial aiming to prevent recurrence and new lung cancers through a vaccine targeting neoantigens.

  7. 25:32
    Extra‑Chromosomal DNA and Targeted Therapies

    Explanation of EC DNA, its role in aggressive cancers, and emerging drugs that target this rogue genetic material.

  8. 28:06
    Optimism and the Future of Cancer Research

    Hosts reflect on the optimism surrounding multi‑front research, immunotherapy breakthroughs, and the potential for future vaccines.

  9. 31:01
    Closing Messages and Call to Action

    Final remarks encouraging hope, community involvement, and support for Cancer Research UK’s ongoing work.

Highlights

  • 1:12

    Unlocking The Blood-Brain Barrierinsight

    The hosts discuss how microbubbles have successfully helped deliver drugs across the blood-brain barrier without invasive procedures, offering a major breakthrough in cancer treatment delivery.

  • 4:54

    From Physics To Medicinestory

    The guest explains her early ambitions to study theoretical physics and astronomy, and why she ultimately pivoted to medicine and human physiology due to a desire for meaningful human interaction.

  • 12:15

    The Mechanism Of Cachexiadata

    The guest explains that cachexia develops in about 80% of advanced cancer patients, hijacking metabolism so the body accelerates the breakdown of fat and muscle tissue to the tumor's benefit.

  • 17:29

    Measuring GDF-15 In Bloodstrategy

    Clinical trials are targeting GDF-15, a specific molecular signal measurable in the blood that regulates appetite and correlates with the development of cachexia in cancer patients.

  • 21:18

    Evolutionary Dead End Metastasesinsight

    Autopsy studies reveal that while some secondary metastases continue to evolve, other metastases in advanced cancer represent evolutionary dead ends, which could change how doctors treat late-stage disease.

  • 26:09

    Targeting Extra-Chromosomal DNAinsight

    Aggressive cancers often feature rogue extra-chromosomal DNA fragments holding oncogenes, and researchers are discovering ways to block their self-sufficient replication and starve them of building blocks.

Quotes

  • “You've got to think big, think ambitiously, be inventive, think laterally, build a community.”
    Unnamed speaker · 0:06
  • “And in fact, some people actually die from cachexia rather than from the tumor itself.”
    Michael Stevens · 2:29
  • “We've begun to map some of the specific molecular signals in the blood.”
    Unnamed speaker · 17:24
  • “It's the first ever lung cancer prevention vaccine.”
    Unnamed speaker · 23:37
  • “Hope, really. You must leave with hope. You've got to think big, think ambitiously, be inventive, think laterally, build a community.”
    Unnamed speaker · 31:20
  • Cancer Research UK 0:25–0:38

About this episode

Why can’t eating more stop someone with cancer from wasting away? In The Rest Is Science’s first ever interview, Professor Hannah Fry and Michael Stevens (Vsauce) sit down with Professor Mariam Jamal-Hanjani, lung cancer specialist and Chief Clinician at Cancer Research UK. Cachexia is a wasting syndrome that affects around 80% of people with advanced cancer. Some patients die from it rather than from cancer itself. Professor Mariam explains how cancer hijacks the body’s metabolism, and how Team CanCan is working towards an “anti-Ozempic”. They also explore what the PEACE autopsy study reveals about how cancer spreads, how the TRACERx study led to LungVax, the first ever lung cancer prevention vaccine trial, and the rogue extrachromosomal DNA (ecDNA) found in aggressive cancers. Along the way: lung cancer in people who’ve never smoked, how immunotherapy changed cancer treatment, and Hannah’s own experience of cervical cancer and what the HPV vaccine could mean for future generations. Could we one day vaccinate against the most common cancers? Mariam says that’s the dream, and she wants everyone to leave with hope. ------------------- For more information about Cancer Research UK, their research, breakthroughs and how you can support them, visit https://cancerresearchuk.org/restisscience Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. ------------------- Find The Rest Is Science all over the internet by ⁠⁠clicking here.⁠⁠ ------------------- Video Producer: Adam Thornton + Oli Oakley + Jack Meek Animator: Sam Benson Video & Social: Bex Tyrrell Producer: Simona Rata + Lucy Lipscombe Senior Producer: Lauren Armstrong-Carter Chief Digital Officer: Samuel Oakley Exec Producer: Neil Fearn Learn more about your ad choices. Visit podcastchoices.com/adchoices

Transcript

0:00
33:39

6,162 words · 3 speakers

Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.

Topics

  • EC DNA
  • LungVax
  • Tracer X
  • microbubbles
  • neoantigens
  • Team CanCan
  • PEACE study
  • P E S research autopsy study
  • smart bras
  • cancer sniffing robots

Page updated · transcript and summary are machine-generated